Las Vegas, December 8, 2018 /PR Newswire – GB Sciences, Inc. (OTCQB: GBLX) currently markets both medical and adult use cannabis products in Nevada under the respected Cultivation Labs brand. The Company has selected and nurtured several cannabis strains that are scoring some of the highest testing lab results seen in the Nevada market, according to the chemoprofile test results from DigiPath Labs.
But this is only one half of the story. By maximizing the production of critical raw materials that can only be derived from the cannabis plant, GB Sciences is able to provide the base materials for their proprietary cannabis-based medical formulations. This breakthrough places cannabis-based medical formulations on a level playing field with traditional medical formulations when it comes to patient studies and clinical trials; a task that, until now, has proven extremely difficult industry-wide.
John Poss, Chairman and CEO stated, “Cannabis-based formulations can now move past anecdotal evidence and instead provide hard, verifiable data to prove safety and efficacy. This changes everything. This is the basis of real medicine.”
The latest proven strain in GB Sciences’ ongoing research is WiFi OG, a 60% sativa dominant hybrid. The tissue propagation unit regenerated the strain using the GB Sciences’ proprietary tissue culture process to get a proper volume of test plants to facilitate research. This process not only ensures zero mold or bacteria in the mother plants, but also allows GB Sciences to create libraries of healthy strains.
The Cultivation Labs unit then placed the strain into their precision controlled growing environments and optimized the strain-specific growing conditions, enhancing the yield of critical components useful in both the recreational market and as the ingredients in the proprietary medical formulations.
“GB Sciences has clearly established that plant husbandry is a key variable that can be exploited to maximize the inherent genetic potential in a given cannabis strain for an enhanced phenotypic outcome as observed in chemoprofiles,” shared Digipath’s Chief Science Officer Cindy Orser, Ph.D.
“It’s no surprise that the test results get better over time as we dial-in the environmental conditions to meet the specific needs of each strain”, said Kevin Kuethe, COO of GB Sciences. “We are now able to modify the environmental controls to allow each specific strain to maximize the production of these key cannabinoids and terpenes.”
Mr. Poss concluded, “GB Sciences was founded on the belief that all people who consume cannabis, regardless of the labels of medical or adult use, are patients of one sort or another. And we could find no one in the industry who had taken the time or made the effort to solve the most basic issue involved in making real medicine… creating pure, trusted, and abundant base ingredients for their medical formulations. Without that element, all the evidence is purely anecdotal. So, this is where we focused our efforts. Research is in our corporate DNA, and it’s beginning to pay off.”
